|
|
، جلد ۴، شماره ۱، صفحات ۱۵-۲۲
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
Evaluating the Effects of Tocilizumab on the Recovery of Hospitalized Patients With Severe COVID-19 in the Cardiorespiratory Intensive Care Unit |
|
| چکیده انگلیسی مقاله |
Background and Aim: In severe COVID-19, the vital organs of the body experience dysfunction, such as respiratory distress, which may lead to the death of the patient. This study investigates the effect of the tocilizumab drug on the recovery of patients with severe COVID-19.
Materials and Methods: This was a retrospective cohort study conducted in Kamkar-Arabnia Hospital, Qom, Iran, in the summer of 2021. The studied data, including age, sex, underlying disease, severity of pulmonary involvement, blood oxygen saturation percentage, duration of hospitalization, need for mechanical ventilation, etc. were extracted and compared with the files of patients with severe COVID-19 who were candidates for receiving tocilizumab according to the national protocol.
Results: 70(50%) patients were men and 70(50%) were women. The mean age of the patients was 55.96±14.18 years. No statistically significant difference was observed between the two groups (P>0.05) regarding clinical symptoms, the mean number of days dependent on a ventilator, the number of days receiving oxygen with a reservoir bag, and the number of days receiving nasal, the number of days hospitalized in the normal department, in the intensive care unit (ICU), as well as the outcome of the patients. No statistically significant difference was observed between the two groups among the laboratory variables of lymph flow and lactate dehydrogenase (P>0.05). However, the C-reactive protein level had a statistically significant difference (P<0.05). A statistically significant difference was observed between the two groups regarding blood oxygen saturation percentage in room air and blood oxygen saturation with auxiliary oxygen (P<0.05).
Conclusion: The results showed that the tocilizumab was effective in the recovery and increasing the amount of blood lymphocytes and blood oxygen of the patients; however, it did not have much effect in reducing the need for an intensive care unit and the outcome of death. For this reason, more clinical trials are required to prove the drug’s effectiveness. |
|
| کلیدواژه‌های انگلیسی مقاله |
COVID-19, Tocilizumab, Respiratory distress syndrome, Intensive care unit |
|
| نویسندگان مقاله |
| Javad Khodadadi
Department of Infectious Diseases, School of Medicine, Kamkar-Arabnia Hospital, Qom University of Medical Sciences, Qom, Iran.
| Amir Hossein Safai Moghadam
Department of Medicine, School of Medicine, Groningen University of Medical Sciences, Groningen, Netherlands.
| Abolfazl Mohammad Beigi
Department of Biostatistics and Epidemiology, Environmental Pollutants Research Center, School of Health, Qom University of Medical Sciences, Qom, Iran.
| Masoud Ahmadi
Department of Infectious Diseases, School of Medicine, Kamkar-Arabnia Hospital, Qom University of Medical Sciences, Qom, Iran.
| Aylar Mohammadi
Department of Biostatistics and Epidemiology, Environmental Pollutants Research Center, School of Health, Qom University of Medical Sciences, Qom, Iran.
| Hamideh Sadat Mirmohammadi
Department of Pediatric Diseases, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
|
|
| نشانی اینترنتی |
http://jvessels.muq.ac.ir/browse.php?a_code=A-10-31-25&slc_lang=fa&sid=1 |
| فایل مقاله |
فایلی برای مقاله ذخیره نشده است |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
fa |
| موضوعات مقاله منتشر شده |
vascular pulmonology |
| نوع مقاله منتشر شده |
پژوهشی |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|